C
hagas' disease is a parasitic infection caused by Trypanosoma cruzi. It is endemic in Mexico, South America, and Central America, where an estimated 16 -18 million people are infected with the disease (1, 2) . Parasitemia follows a bite by an infected kissing (reduviid) bug. In the acute phase fever is the most common clinical manifestation of the disease, although approximately 20% of those infected are completely asymptomatic (3) . Rarely, patients succumb to the acute phase of infection secondary to severe heart failure or encephalomyelitis (usually children and immunocompromised patients) (1) (2) (3) . Infection leads to T cell activation as well as antibody formation. These immune responses promote a latency or indeterminate phase in most patients, while a susceptible minority develops chronic infection leading to potentially lethal cardiomyopathy and megasyndromes (megacolon, megaesophagus).
Trypanosomes circulating in the blood make bloodborne transmission a possibility. The first transmission by blood transfusion occurred in Brazil in 1952. Since then, nearly 200 cases have been reported in Latin America, which is assumed to be a severe underestimation (3) . The dangers of transmission are increased because this disease is often subclinical, causing many donors to be unaware of their infection status. In 1993, a study of 318 blood donors in Morelos, Mexico showed that 17% of donors had antibodies to T. cruzi detected by a commercial enzyme immunoassay (EIA) (4).
Reports of transmission of T. cruzi by organ transplantation inevitably followed, although screening in Latin America for the parasite is standard practice (1, 2, (5) (6) (7) (8) .
Reports of blood and donor organ transmissions have surfaced in the United States and Canada. There have been three reported cases of transfusion transmission of T. cruzi. Two cases were in the United States, occurring in a patient with Hodgkin's disease and a bone marrow transplant patient, both with clinical manifestations of infection (3, 9) . The third case was from Canada, in a patient with acute lymphocytic leukemia who developed acute Chagas' disease (10) . In all cases the suspected blood donors had emigrated from T. cruzi endemic areas.
In March of 2002, the Centers for Disease Control (CDC) reported a case in which three solid organ transplant recipients were infected with T. cruzi from a single organ donor (1). The donor was an immigrant from Central America assumed to have been infected with T. cruzi. One of the recipients, a 37-year-old female, developed a febrile illness and continued to suffer bouts of symptomatic parasitemia despite treatment for T. cruzi. She eventually died from acute Chagasic myocarditis. The other kidney recipient was successfully treated, and the recipient of the liver died of unrelated causes. This recent report has increased awareness of the possibility of organ transplant transmission of a potentially fatal disease.
Chagas' disease is of special concern in Southern California, where there is a large immigrant population from countries where T. cruzi is endemic. According to the year 2000 Census, nearly 7 million respondents in the relevant Southern California counties considered himself or herself Hispanic or Latino (11) . In the entire state of California, from 1988 to present, 25% of organ donors were Hispanic (12) . In addition to this large population there are frequent contacts of non-Hispanics with areas where T. cruzi is endemic.
Currently there is no United Network for Organ Sharing (UNOS) policy or CDC recommendations concerning the serologic screening of potential organ donors for T. cruzi in the United States. However, EIA have been used in research and clinical application in the United States for several years and confirmatory immunofluorescence assay (IFA) is available at the CDC. As the proportion of Hispanic organ donors is very high in our population, we decided to evaluate the seroprevalance of anti-T. cruzi antibodies among the cadaver solid organ donors to determine the risk of infection.
MATERIALS AND METHODS
We tested all 404 archived serum samples from deceased organ donors sent to our laboratory by the Organ Procurement Organization (OPO) between May 2002 and April 2004. This OPO recruits donors from the Southern California area (Kern, Santa Barbara, Ventura, Los Angeles, Orange, Riverside, San Bernadino). The composition of our cohort reflects the ethnic diversity of the population living in this area. Median age was 34 years and 41% of donors were Hispanic. All serum samples from prospective organ donors were screened for antibodies to T. cruzi, using a commercial EIA (Hemagen Diagnostics, Columbia, MD). The assay was carried out following the manufacturer's instruction. In Figure  1 , we provide the distribution of sample absorbance to cut-off ratios (S/CO) for all tested specimens. The figure shows the separation of S/CO for reactive and nonreactive samples. Because of the poor separation between reactive and nonreactive samples, we decided to repeat in duplicate all specimens with absorbance within 10% above and below the cutoff value. Cross-reactive antibodies against Leishmania species and other trypanosomal agents were not determined. All repeatedly reactive specimens were sent for confirmatory testing to the CDC Microbial Disease Laboratory (Atlanta, GA), where a confirmatory testing was performed. The confirmatory assay has a cut off of Ն1:32 dilution and utilizes fixed epimastigotes to confirm specificity of anti-T. cruzi EIA reactivities.
RESULTS
In Table 1 we provide results from our screening. From 404 cadaveric donor specimens available for testing, six were initially reactive or gray zone reactive with the EIA. Three specimens were repeatable reactive when re-tested in duplicate and were sent to the CDC for confirmatory testing. One specimen's initial EIA reactivity was confirmed to be weakly reactive (titer 1/64) by IFA. The ages for the initially reactive donor specimens ranged from 40 -61 years old. The majority was male (5/6), and three out of the six specimens were from Hispanic donors. The confirmed reactive specimen was from a 45 year-old male Hispanic donor. The OPO has been notified of the results of our study, and tracking of the organs from the positive donor specimen is in progress.
DISCUSSION
Organ donor screening algorithms for the prevention of common communicable diseases are well described. However, in the past few years, the transmission of other rare, but potentially fatal diseases has raised the question of whether current screening policies are adequate. The first report of transmission of West Nile virus (WNV) by blood and solid organs occurred in 2002 (13) . Three organ recipients developed encephalitis and one developed a febrile illness following transplantation. Blood banks have begun using nucleic acid amplification testing to screen for WNV, and potential blood donors are asked about fever and headache symptoms during mosquito season. Organ donors, however, do not undergo serological screening for WNV.
In 2004, a single donor transmitted rabies virus to three solid organ recipients and one recipient of a vascular graft (14) . All four recipients experienced neurological symptoms and died within 2 weeks of onset of symptoms. Rabies virus, although not spread hematologically, is a risk for organ transplantation. Screening should entail detailed questions about a history of mammalian bites.
To our knowledge, our study is the first evaluation of anti-T. cruzi antibodies seroprevalence among cadaveric organ donors from the United States West Coast. With increased emigration to the United States the risk of Chagas' disease transmission is no longer a problem limited to Latin America. A study of 1024 consecutive blood donors at the Los Angeles County blood bank showed a seroreactivity to T. cruzi of 1.1%, and a confirmed reactivity of 0.1%. Donors from T. cruzi-endemic countries composed 38% of the sample donor population (15) . We found one donor (0.25%) with a confirmed level of anti-T. cruzi reactivity. All initially reactive specimen S/CO ratios were low which is compatible with old exposure (1). Our data suggest that screening for T. cruzi should be triggered by donor risk factors like the strength of the ethnic ties with endemic areas to avoid unnecessary exclusion of donors due to unconfirmed EIA screening results. There is currently no accepted screening or confirmatory tests for T. cruzi. Although EIA screening is not time or cost-prohibitive, future studies are needed to determine the suitability of these tests in both endemic and nonendemic areas.
Our data is in contrast with the previously published data from the United States. Bryan et al. from the Midwestern United States found no organ donors with antibodies to T. cruzi over a 6.5-year period (16). Barrett et al. screened 8000 random blood donor samples in the Southeast United States and had no samples with T. cruzi antibodies (17, 18) . This discrepancy is likely secondary to differences in pop- ulation composition, as Southern California has a large Hispanic and Latino immigrant population. Similar to the issues discussed with the documented transmission of WNV and rabies, the organ transplant transmission of T. cruzi raises the question of adequate screening of donors for this disease. The risks involved with possible transmission are high in transplant patients, as immunosuppression has been shown to exacerbate T. cruzi infection (19) . Transmission infection with T. cruzi has led to death in previous cases of immunosuppressed patients. According to our data and previous case reports, screening donors from T. cruziendemic countries for anti-T. cruzi antibodies may be beneficial in areas with a high frequency of these organ donors.
